Leonor Ramos

Leonor Ramos

Auto-generated profile, based on publicly available information

Leonor Ramos

Department of Dermatology, Coimbra University Hospital, Unidade Local de Saúde de Coimbra, Coimbra, Portugal

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 December 2024 in Journal of Pediatric Genetics
Verified
Journal Article
Closed access
PDF file
MLManuela S. Lopes
Manuela S. Lopes
CMCátia Martins
Cátia Martins
AFAna Ferraz
Ana Ferraz
JRJoana Rosmaninho-Salgado
Joana Rosmaninho-Salgado
RCRui Castelo
Rui Castelo
LRLeonor Ramos
Leonor Ramos
Epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein that exhibits tyrosine kinase signaling activity, playing a pivotal role in various cellular processes. Overexpression or overactivity of EGFR is significantly associated with inflammatory and malignant diseases, particularly lung cancer. Conversely, germline loss-of-function mutations in EGFR have been distinctly linked to a rare condition known as neonatal nephrocutaneous syndrome. We report a case of a preterm female neonate, born to consanguineous parents and from a pregnancy that was complicated by polyhydramnios. From birth, she displayed distinctive clinical features, including fragile skin and widespread erythema, sparse scalp hair, bilateral ankyloblepharon, thick eyebrows, and arachnodactyly. Subsequently, she developed progeroid features marked by skin desquamation, along with failure to thrive, diarrhea, and severe electrolyte and acid–base imbalances. Additional complications comprised anemia, generalized mucocutaneous candidiasis, external otitis, and recurrent septic episodes. Genetic analysis confirmed a homozygous EGFR mutation c.1283G > A p.(Gly428Asp). The infant's neurological status remained stable, albeit requiring pain management through oral morphine and gabapentin. Palliative care became imperative, given the dismal prognosis. The identified mutation is exceedingly rare, with only 24 reported cases known thus far. Each of these instances resulted in a complex multisystemic condition marked by a wide range of challenging symptoms and signs. This clinical journey highlights the intricate interplay among genetic mutations and complex medical conditions, and underscores the critical significance of multidisciplinary care.

1 July 2015 in Journal of the Portuguese Society of Dermatology and Venereology
Verified
Journal Article
Open access
PDF file
LRLeonor Ramos
Leonor Ramos
MGMiguel Gouveia
Miguel Gouveia
JCJosé Carlos Cardoso
José Carlos Cardoso
MCMargarida Robalo Cordeiro
Margarida Robalo Cordeiro
Dermatomyositis is a systemic autoimmune disease with cutaneous, muscular and pulmonary involvement. MDA-5 has recently been described as a specific dermatomyositis target antigen associated with a higher risk for interstitial lung disease. A 54-year-old female patient presented with proximal muscular weakness, myalgia and cutaneous signs of dermatomyositis. She presented with high aldolase and CK levels, and the muscular biopsy and electromyography were consistent with dermatomyositis. Pulmonary CT scan showed ground glass appearance. Autoimmunity revealed strong anti-MDA-5 positivity. No neoplasm was detected. She began treatment with prednisolone 20mg, hydroxicloroquine 400mg and methotrexate 20mg/week with very little improvement. She then began IVIG, with better clinical response. The authors report a case of dermatomyositis with interstitial lung disease associated with anti-MDA-5, an association unknown until recently.

18 February 2026 in medRxiv
Verified
Preprint
Open access
PDF file
DCDiana Caieiro
Diana Caieiro
NFNuno A. Faria
Nuno A. Faria
ABAna Botelho
Ana Botelho
MAMariana Araújo
Mariana Araújo
LRLeonor Ramos
Leonor Ramos
MMMaria Miragaia
Maria Miragaia
Staphylococcus aureus plays a central role in the exacerbation of atopic dermatitis (AD), but the population structure and pathogenic determinants of strains colonizing AD patients remain poorly understood. It is unclear whether these strains mirror those circulating in the general community or whether specific clonal lineages are selectively adapted to the AD skin microenvironment. Data addressing this question are scarce, particularly in Portugal. In this study, we investigated the molecular epidemiology and pathogenic traits of S. aureus colonizing skin lesions in adult patients with AD in Portugal. We found that lesion-associated isolates belonged predominantly to the methicillin-susceptible S. aureus MSSA-ST398 clonal type, a lineage that is widely circulating in the Portuguese community, particularly among vulnerable populations, and that has also been implicated in severe human infections. Notably, isolates from this clonal type in AD harboured specific pathogenicity traits associated with skin barrier disruption, including hemolysin and urease production, which may contribute to their success as colonizers in AD. Our findings highlight that S. aureus colonization in AD arises from a dynamic interplay between community-level molecular epidemiology and disease-specific selective pressures. While circulating lineages provide the genetic background diversity, the AD skin microenvironment appears to shape which clones ultimately become dominant. Such an integrated perspective may help to inform future geographically tailored strategies aimed at limiting bacterial burden and preventing disease exacerbation in AD.

1 January 2022 in Pediatric Oncall
Verified
Journal Article
Open access
CPCrisbety Pinho
Crisbety Pinho
JSJoana N Santos
Joana N Santos
LRLeonor Ramos
Leonor Ramos

1 January 2025 in Dermatologic Therapy
Verified
Journal Article
Open access
JTJoão Teixeira
João Teixeira
AAAndré Aparício-Martins
André Aparício-Martins
MPMariana Pedroso
Mariana Pedroso
CFCarolina Figueiredo
Carolina Figueiredo
FSFelicidade Santiago
Felicidade Santiago
LRLeonor Ramos
Leonor Ramos
Dupilumab, a monoclonal antibody targeting interleukin‐4 receptor alpha, has shown both robust efficacy and safety in pediatric atopic dermatitis (AD), but data on complete disease control (Eczema Area and Severity Index [EASI] 100) are scarce. A retrospective analysis of 25 pediatric patients at our institution with a median treatment duration of 20 months revealed a significant improvement in EASI scores, with 44.0% achieving EASI 100 at a median of 52 weeks of treatment. No significant differences were found between the group of patients achieving EASI 100 and those who did not. While this study provides additional insight into the efficacy and safety of dupilumab in pediatric AD, its limited sample size underscores the need for larger scale studies focusing on EASI 100 to better understand the factors influencing complete disease control and to optimize treatment strategies for pediatric patients with AD.